Can Enasidenib be purchased in Myanmar?

Enasidenib(Enasidenib) is not currently available in Myanmar and therefore is not available for purchase in Myanmar. Ensidipine is an isocitrate dehydrogenase 2 (id H2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML). A New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2016. It was accepted for review in March 2017 and approved in August 2017 for the treatment of relapsed or refractory (R/R) AML.

Acute myeloid leukemia is a blood cancer that starts in the bone marrow and can quickly spread to other parts of the body. In most cases, AML patients will experience relapse. IDH2 mutations are typically found in 8% to 19% of AML cases. Symptoms of the disease include fever, easy bleeding, shortness of breath, weight loss, loss of appetite and weakness. Ensidipine contains a small molecule inhibitor of isocitrate dehydrogenase 2 (id H2), which works against mutated IDH2 variants to reduce 2-hydroxyglutarate levels and increase the percentage of mature bone marrow cells. Ensidipine is available in 100 mg oral tablets.

Ensiidi plain investigational medicine is not currently on the market in the country, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad. For more information on overseas drug prices and specific information, please consult Yaode Medical Consultant.